Coverage
Filings
| Filing | Date |
|---|---|
| Block listing Interim Review | 1 Oct 2024 |
| Director/PDMR Shareholding | 24 Sept 2024 |
| Hikma completes Xellia acquisition | 10 Sept 2024 |
| Director/PDMR Shareholding | 13 Aug 2024 |
| Half-year Report | 8 Aug 2024 |
| Director Declaration | 29 Jul 2024 |
| Notice of Results | 15 Jul 2024 |
| Total Voting Rights | 1 Jul 2024 |
| Director Declaration |
Hikma Pharmaceuticals lowered its medium-term profit growth forecast, citing delays at a new manufacturing facility in the U.S.
| 27 Jun 2024 |
| Hikma acquires Xellia’s assets | 17 Jun 2024 |
| Director/PDMR Shareholding | 5 Jun 2024 |
| Director/PDMR Shareholding | 9 May 2024 |